Deep venous thrombosis and pulmonary embolism
TO THE EDITOR: It is with great interest that we have read the clinical article by Rolston et al. 10 (Rolston JD, Han SJ, Bloch O, et al: What clinical factors predict the incidence of deep venous thrombosis and pulmonary embolism in neurosurgical patients ? J Neurosurg 121:908-918, October 2014) . They have investigated risk factors for venous thromboembolisms (VTEs) in neurosurgical patients using a large data set acquired from the American College of Surgeons' National Surgical Quality Improvement Program database over a 5-year period.
10 In 1.7% of the 38,058 neurosurgical cases they observed, VTE became clinically evident within 30 days after surgery. Due to the apparent risks of intracranial hemorrhages, neurosurgeons are overly cautious in their use of perioperative anticoagulant and/ or antithrombotic agents. Nevertheless, the complications of a VTE, such as deep venous thrombosis or pulmonary embolism, have great impact on outcome in terms of morbidity and mortality. In a recent study we observed 90-day overall mortality rates of 5.0% and 23.1% when deep venous thrombosis and pulmonary embolism, respectively, occurred in patients who had undergone cranial meningioma resection. 8 Interestingly, the authors established steroid use as a risk factor for VTE. They suggested this might be due to "a variety of increased procoagulant factors." 10 Indeed, there are some reports corroborating these findings and suggesting that steroids produce a hypercoagulable state in patients. 4, 11, 12 Since the landmark report of Galicich et al. in 1961, high-dose corticosteroids are routinely administered to patients undergoing cranial surgery. 7, 9 More recently, a renewed interest in the use of corticosteroids for both the medical treatment and perioperative medical treatment of chronic subdural hematoma (CSDH) has been sparked. 2, 5, 6 This usage raises some major questions when considering the potential VTE complications. Several comments on the use of glucocorticoids and the risk of VTE should be made, despite the findings of Rolston et al.
First, Rolston et al. could not define, and therefore not investigate, steroid use, because the pathology they investigated is subject to significant variation. Moreover, there is no information on dose and duration of treatment.
Second, to date, there is only one extensive review of literature by van Zaane et al. that attempts to shed light on this topic.
13 However, the findings therein are tempered, as the authors state, by the lack of high-quality randomized trials. Nevertheless, they have shown that glucocorticoids tend both to lower the levels of several procoagulant factors, such as von Willebrand factor and fibrinogen, and simultaneously to give rise to an impaired fibrinolytic activity through increasing the levels of plasminogen activator inhibitor-1 (PAI-1). Thus, the net result of these mechanistic actions of corticosteroids on the coagulation system is not necessarily prothrombotic, or at least not adding to the thrombotic risk imposed by the surgery itself.
13 Third, in a previous study, 3 we observed that in patients who underwent surgery for CSDH, and who were concomitantly treated with high-dose glucocorticoids, the incidence of VTE was 1.8%, which supports the findings of Rolston et al. 10 In these patients, we have found that both VTE and mortality were in fact not related to the duration of high-dose corticosteroid use. On the contrary, in patients operated on for intracranial meningiomas, all treated with perioperative corticosteroids, the occurrence of VTE was 7.2%. 8 This difference in VTE occurrence between these two conditions, with the same corticosteroid regimen, probably reflects the patient's hypercoagulable state in tumor surgery and thus underlines the importance of the pathology at hand rather than corticosteroid administration itself. 1, 8 Considering the above, we believe that further research is needed to assess the risk-benefit ratio of glucocorticoid use in neurosurgical practice, which requires a well-designed randomized controlled trial and clinical outcome studies. Additionally, we strongly suggest that VTE complications should be assessed as a major outcome, related to mortality and quality of life, in such studies to assess the effects of glucocorticoid treatment in a dose-and timedependent manner. 
Response
No response was received from the authors of the original article. The readmission rate is a commonly used quality measure, even though whether it actually leads to quality improvement has been challenged.
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3 The rates can appear to be significantly different depending on the study methodologies, and one way to differentiate them is from the standpoint of big data.
The rise of big data has been a topic of many excellent essays.
2 Some of the characteristics of the studies at the two extremes of the data size spectrum are shown in Fig. 1 . While the surgical literature is traditionally filled with case series near the right end of the spectrum, more and more policy-making decisions and studies are based on large databases. However, there is a trade-off between having pristine data and data drawn from a large sample size. This is particularly troubling for the clinicians, who, more than anyone else, are aware that clinical and social nuances are what make each patient unique and often influence outcome. Some of these factors have not yet been quantified (i.e., surgeon fatigue), and some are quantified with rudimentary scales (i.e., ASA physical status classification system). Finally, the utility of these databases hinges on information being entered accurately, which is not always the case.
Along this line of thinking, here are a few specific comments on the aforementioned studies: 1. In the study by Marcus et al., 4 which utilized a statewide database to examine readmissions after supratentorial tumor resection (n = 18,506), they found that seizure was a main cause of readmission based on readmission ICD-9 codes. Do the authors have enough confidence in the validity of seizure diagnoses in this kind of database to recommend targeted prospective intervention? 2. Shah et al. 5 and Buchanan et al. 1 gathered detailed information on patients who were readmitted (n = 407 and n = 365, respectively) in their respective institutions. Information was not gathered to the same extent for the rest of the patients in the cohort who were not readmitted (n = 3552 and n = 5569). The detailed descriptions enabled the authors to offer their expert opinions on adjudicating preventability, an important topic of its own. However, in the absence of direct comparison between patients with and without the adverse events (readmis-
